Symptoms of low testosterone in women: why desire is the only one the trials back
A blood test will not tell you whether low testosterone is behind your symptoms. No lab cutoff exists for women, and the 2019 global consensus on testosterone therapy tells doctors not to diagnose from the number at all.
That gap explains why so many women over 40 search for the symptoms of low testosterone in women, find a list of twelve, and then get turned away by their doctor. Testosterone in women falls with age, starting in the twenties. Natural menopause does not cause a sudden drop. Surgical removal of the ovaries does. And of every symptom on the popular lists, only one has randomized trial evidence showing that testosterone treatment improves it.
This article explains what testosterone does in a woman's body, which symptoms of low testosterone in women the research supports, and what testing and treatment look like under the 2019 global consensus that governs how doctors prescribe it.
| Claim | Evidence |
|---|---|
| Testosterone falls with age, not with natural menopause | A study of 1,423 women aged 18 to 75 found the steepest decline in the early reproductive years and no independent effect of menopause in women 45 to 54 |
| Removing both ovaries lowers testosterone | Women 55 and older with bilateral oophorectomy had lower total and free testosterone than women with intact ovaries |
| Low sexual desire with distress is the only proven indication | The 2019 global consensus names hypoactive sexual desire disorder in postmenopausal women as the sole evidence-based use |
| The benefit is measurable but modest | Trials show about one extra satisfying sexual event per month over placebo |
| No FDA-approved testosterone product exists for women | US prescriptions are off-label, usually a fraction of a men's dose |
| Fatigue, weight gain and brain fog lack trial support | The consensus found insufficient evidence to recommend testosterone for any outcome other than desire |
- What testosterone does in a woman's body, and when it falls
- Symptoms of low testosterone in women: what the evidence links to it
- Testing and treating low testosterone in women under the 2019 consensus
- Testosterone therapy vs. other routes for low desire
- Where Botavive Desire fits when low desire is the symptom
- Frequently asked questions
What testosterone does in a woman's body, and when it falls
Women make testosterone in three places: the ovaries, the adrenal glands, and peripheral tissue such as fat and skin, which converts precursor hormones like DHEA into testosterone. A woman's blood level runs at roughly one tenth to one twentieth of a man's. Small amounts still matter. Testosterone acts on receptors in the brain, the genital tissue, bone and muscle, and the body converts part of it into estradiol.
The timing of the decline surprises most women. A 2005 study in the Journal of Clinical Endocrinology and Metabolism measured testosterone, free testosterone, DHEA sulfate and androstenedione in 1,423 randomly recruited Australian women aged 18 to 75. Levels fell steeply through the early reproductive years. By the forties, most of the drop had already happened.
Menopause itself did little. When the researchers compared women aged 45 to 54 by menopausal status, being pre or postmenopausal had no independent effect on androgen levels. The postmenopausal ovary kept producing testosterone.
That last point changes who is at real risk. In the same study, women 55 and older who had both ovaries removed, and who were not taking hormones, had lower total and free testosterone than women of the same age with their ovaries intact.
The practical reading: a woman who goes through menopause naturally has roughly the testosterone she had at 45. A woman who loses her ovaries to surgery loses a source her body would otherwise keep using for decades.
Symptoms of low testosterone in women: what the evidence links to it
Search results for the symptoms of low testosterone in women list fatigue, weight gain, brain fog, thinning hair, low mood, muscle loss, poor sleep and low libido. Most of those symptoms also belong to perimenopause, thyroid disease, iron deficiency, poor sleep and depression. A list that broad describes half the women over 40 in any waiting room.
The research sorts them into two groups.
Low sexual desire with distress. This is the one symptom with Level I evidence. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 and endorsed by the Endocrine Society, the International Menopause Society and more than a dozen other bodies, reviewed placebo-controlled trials and concluded that testosterone improves desire, arousal, orgasm, pleasure and responsiveness in postmenopausal women diagnosed with hypoactive sexual desire disorder. The clinical name matters. HSDD means a persistent loss of desire that causes the woman distress, after other causes have been ruled out.
Everything else. Fatigue, low motivation, muscle loss, mood, cognition, bone density and weight: the consensus found the evidence insufficient to recommend testosterone for any of them. That does not prove testosterone plays no role. It means the trials that would show a benefit have not produced one yet.
These raise the odds that testosterone, and not something else, is part of the picture:
- Surgical menopause, meaning both ovaries removed
- Oral estrogen or oral contraceptives, which raise sex hormone binding globulin and lower the free testosterone available to tissue
- Pituitary or adrenal disorders
- Long-term high-dose corticosteroid use
Women over 40 describe the same pattern again and again: a doctor declines testosterone, the woman pushes back with a list of symptoms, and the conversation stalls. The stall usually happens because only one item on her list fits the prescribing criteria.
Testing and treating low testosterone in women under the 2019 consensus
The blood test. The consensus advises against using a total testosterone level to diagnose HSDD. Many standard lab assays were designed for male ranges and read poorly at the low concentrations found in women. A test still has a job: a baseline measurement before treatment, and a check during treatment to keep the dose inside the normal premenopausal range.
The diagnosis comes first. A doctor following the consensus starts with a full assessment: relationship factors, pain with sex, depression, sleep, and medications such as SSRIs that blunt desire. Testosterone enters the plan when HSDD remains after those are addressed.
The form of testosterone. The consensus prefers transdermal products, gels or creams applied to the skin, at doses that keep blood levels within premenopausal norms. It recommends against oral testosterone, injections and pellets, all of which push levels above that range. It also recommends against compounded products because their dose and purity are not standardized.
The US gap. The FDA has not approved any testosterone product for women. American doctors who prescribe it use a men's gel at roughly one tenth of the male dose, off-label. That is one reason some women hear "no" from one doctor and "yes" from another.
The timeline. The consensus recommends rechecking blood levels at three to six weeks, and stopping treatment if there is no benefit by six months.
Pro Tip: Before the appointment, write down when the loss of desire started, whether it bothers you or your partner more, and every medication you take. A doctor applying the consensus will ask all three, and an answer on paper moves the visit past the stall point.
Testosterone therapy vs. other routes for low desire
Low desire after 40 rarely has one cause, so the treatment rarely has one piece. Painful sex from vaginal dryness suppresses desire as surely as any hormone, and no amount of testosterone fixes pain.
| Approach | Pros | Considerations | Best for |
|---|---|---|---|
| Transdermal testosterone | Level I evidence for HSDD | Off-label in the US, needs blood monitoring, acne or extra hair growth at higher doses | Postmenopausal women with diagnosed HSDD |
| Compounded creams or pellets | Widely available through clinics | Not recommended by the consensus, doses not standardized, pellets run above female range | Not advised |
| Vaginal estrogen | Treats dryness and pain directly, low systemic absorption | Prescription required, does not target desire itself | Low desire caused by painful sex |
| Sex therapy and medication review | No hormones, addresses relationship and drug causes | Takes several sessions, access varies by area | Every woman with low desire, as a first step |
| Botanical supplements | Hormone-free, no prescription | Smaller trials, effects vary by extract and dose | Women who want a non-hormonal option or are waiting on evaluation |
The approaches stack. A woman on vaginal estrogen for dryness who still has low desire is a candidate for a testosterone trial. A woman on an SSRI might see desire return after a medication change, with no hormone involved.
Testosterone and systemic estrogen therapy are often prescribed together. The consensus did not rule on the combination, so the decision belongs to the prescribing doctor.
Know when to seek professional evaluation:
- Loss of desire that has lasted six months or longer and causes distress
- Pain during sex, or bleeding after sex
- Both ovaries removed, at any age
- New acne, scalp hair loss, a deepening voice or facial hair growth while using testosterone
- Low desire alongside low mood, hopelessness or loss of interest in other activities
- A lab result showing testosterone above the female reference range
Where Botavive Desire fits when low desire is the symptom
Most women who wonder about low testosterone are asking about one thing: desire that faded and has not come back. Some will qualify for testosterone. Many will not, either because they are still in perimenopause, where the consensus found too little evidence, or because they prefer a hormone-free route while they work through an evaluation.
Botavive Desire is a hormone-free formula built for that second group. It contains no testosterone and does not raise testosterone. Its 802 mg botanical blend includes Tribulus terrestris, maca, epimedium, Asian ginseng, damiana and ashwagandha, alongside zinc and B vitamins. Tribulus has the most direct research in this population: in a 2016 randomized, placebo-controlled trial of 60 postmenopausal women with sexual dysfunction, 90 days of a dedicated tribulus extract raised desire and sexual interest scores to 10.2, against 7.6 on placebo, with gains in arousal and comfort. Orgasm and satisfaction scores did not differ. Desire's blend does not list the amount of each herb, so its dose is not the same as the trial's.
Botavive Desire is formulated to heighten sexual response, support blood flow maintenance and promote stress relief. It works best as one part of a plan that also covers sleep, pain, medications and the relationship itself.
Frequently asked questions
What does low testosterone in women mean?
It usually means a blood level near or below the bottom of a lab's female reference range. On its own, that number is not a diagnosis. The 2019 consensus treats low desire with distress, diagnosed after other causes are ruled out, as the condition that testosterone treats.
What testosterone level is considered low for a woman?
No agreed cutoff exists. Reference ranges differ between labs and assays, and many standard tests were built for male concentrations. For that reason the consensus advises against diagnosing from the number.
Does perimenopause lower testosterone?
Not much. A study of 1,423 women found that most of the decline happens in the twenties and thirties, and menopausal status had no independent effect in women aged 45 to 54. Surgical removal of both ovaries is the event that lowers it.
Does low testosterone in women cause weight gain?
The trials do not support that link. The consensus found insufficient evidence to recommend testosterone for weight, body composition or metabolic outcomes. Midlife weight gain has stronger ties to estrogen decline, sleep, muscle loss and insulin resistance.
How long does testosterone take to work for women?
Doctors following the consensus recheck blood levels at three to six weeks and judge the response over several months. If desire has not improved by six months, the recommendation is to stop.
Sources
- Davison SL, Bell R, Donath S, Montalto JG, Davis SR, 2005. Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology and Metabolism. pubmed.ncbi.nlm.nih.gov/15827095
- Davis SR, Baber R, Panay N, et al., 2019. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology and Metabolism. pmc.ncbi.nlm.nih.gov/articles/PMC6821450
- Postigo S, Lima SMRR, Yamada SS, et al., 2016. Assessment of the effects of Tribulus terrestris on sexual function of menopausal women. Revista Brasileira de Ginecologia e Obstetrícia. pmc.ncbi.nlm.nih.gov/articles/PMC10309463